Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 10:15:1122300.
doi: 10.3389/fnagi.2023.1122300. eCollection 2023.

Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development

Juan Huang  1   2   3 , Nanqu Huang  4 , Di Cui  2 , Jingshan Shi  2 , Yu Qiu  1
Affiliations
Review

Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development

Juan Huang et al. Front Aging Neurosci. .

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.

Keywords: Alzheimer’s disease; antidiabetic medication; clinical research; type 2 diabetes mellitus; type 3 diabetes mellitus (T3DM).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Akimoto H., Negishi A., Oshima S., Wakiyama H., Okita M., Horii N., et al. (2020). Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am. J. Alzheimers Dis. Other Demen. 35:1533317519899546. 10.1177/1533317519899546 - DOI - PMC - PubMed
    1. An J., Zhou Y., Zhang M., Xie Y., Ke S., Liu L., et al. (2019). Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer’s disease. Behav. Brain Res. 370:111932. 10.1016/j.bbr.2019.111932 - DOI - PubMed
    1. Ates Bulut E., Sahin Alak Z. Y., Dokuzlar O., Kocyigit S. E., Soysal P., Smith L., et al. (2020). Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study. Arch. Gerontol. Geriatr. 88:104013. 10.1016/j.archger.2020.104013 - DOI - PubMed
    1. Badhwar A., Brown R., Stanimirovic D. B., Haqqani A. S., Hamel E. (2017). Proteomic differences in brain vessels of Alzheimer’s disease mice: normalization by PPARγ agonist pioglitazone. J. Cereb. Blood Flow Metab. 37 1120–1136. 10.1177/0271678x16655172 - DOI - PMC - PubMed
    1. Batista A. F., Forny-Germano L., Clarke J. R., Lyra E. S. N. M., Brito-Moreira J., Boehnke S. E., et al. (2018). The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J. Pathol. 245 85–100. 10.1002/path.5056 - DOI - PMC - PubMed

LinkOut - more resources